About: Biosimilar medicines
OpinionPromoted content
Access to medicines: Let’s have better care, for more patients
Marc-Alexander Mahl is President of Medicines for Europe. Europe’s healthcare model is under pressure. Populations are ageing in Europe – with the number of Europeans aged 65 or over set to rise by 45 million between 2015 and 2050.(1) This...
New Commission study fuels generic drugs industry ‘manufacturing dispute’
The European Commission launched on Thursday (12 October) a public consultation on supplementary protection certificates for pharmaceutical products and the so-called Bolar patent research exemption.
Pharma expert: EU drug agency should be ‘easily’ accessible to all
Any country that wants to inherit the European Medicines Agency (EMA) from London has to be easily accessible. Candidates will also need to increase their national agency’s resources, as staff are expected to move to the EMA, according to Adrian van den Hoven.
Pharma boss: Some EU countries effectively delay market entry of generics
The harmonisation of different regulatory environments in the EU member states will help generic drugs enter the market, resulting in reduced prices for medicine and better patient access, Jacek Glinka told EURACTIV.com in an interview.
Italy’s pharma scandal heats up drugs pricing debate
The European Consumer Organisation (BEUC) has urged the European Commission to investigate pharma-industry “unethical” practices on drug pricing, after a scandal revealed last week in Italy.
Pharma industry ‘cannot escape’ drug price talks, say patient groups
Patient groups and the pharmaceutical sector agree that access to medicines needs to be improved - but the way to do it seems to divide them. EURACTIV.com reports from Sofia.
Bulgarian health minister: Drugs availability part of regional cooperation
Bulgaria and Romania will soon sign an intergovernmental agreement to jointly negotiate the pricing and availability of medicines with pharmaceutical companies, Bulgarian Health Minister Petar Moskov said in an interview with EURACTIV.com.
Pharma expert: new ‘value added medicines’ offer cheaper, customised treatment
A new breed of drugs, called “value added medicines”, could help patients improve their everyday life while in treatment, without increasing healthcare budgets, Christoph Stoller said in an interview with EURACTIV.com